A5022937823- Systemic Lupus Erythematosus Research
- Renal Diseases and Glomerulopathies
- Liver Diseases and Immunity
- Atherosclerosis and Cardiovascular Diseases
- Autoimmune Bullous Skin Diseases
- Vasculitis and related conditions
- Pregnancy and Medication Impact
- Monoclonal and Polyclonal Antibodies Research
- Chronic Kidney Disease and Diabetes
- Inflammatory Bowel Disease
- T-cell and B-cell Immunology
- Delphi Technique in Research
- Complement system in diseases
- Archaeological and Geological Studies
- Ocular Infections and Treatments
- Renal and Vascular Pathologies
- Hepatitis C virus research
- Health Systems, Economic Evaluations, Quality of Life
- Immunotherapy and Immune Responses
- Corneal surgery and disorders
- Corneal Surgery and Treatments
- Dialysis and Renal Disease Management
- Ocular Surface and Contact Lens
- Celiac Disease Research and Management
- Historical and Cultural Archaeology Studies
Hospital Fernández
2014-2024
Fernandez Hospital
2024
Hospital Universitari i Politècnic La Fe
2023
The Ohio State University
2020
RELX Group (United States)
2019
Universidade de Santiago de Compostela
1989-1993
In adults with active lupus nephritis, the efficacy and safety of intravenous belimumab as compared placebo, when added to standard therapy (mycophenolate mofetil or cyclophosphamide–azathioprine), are unknown.
Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised II monoclonal antibody that induces potent B-cell depletion, with placebo for the treatment LN combination standard therapies.Patients receiving mycophenolate corticosteroids were randomised obinutuzumab 1000 mg or on day 1 weeks 2, 24 26, followed through week 104. The primary endpoint was complete renal response (CRR)...
The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. conference focused the 2012 KDIGO guideline with aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, particular, therapy since guideline's publication. It was consensus group that most recommendations, particular those dealing therapy, will need to be revisited by guideline-updating Work Group. This report covers...
Treatment response in lupus nephritis (LN) is defined clinically, without consideration of renal histology. Few studies have systematically examined histologic responses to induction therapy. In LN patients who underwent protocol kidney biopsies after immunosuppression, we describe the histology second biopsy and correlate activity damage with short- long-term outcomes.
In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss 2012 KDIGO glomerulonephritis guideline context new developments and insights that had occurred over years since its publication. During this Controversies Conference on Glomerular Diseases, group examined data disease pathogenesis, biomarkers, treatments identify areas consensus controversy. This report summarizes discussions...
We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN), Phase 3, multinational, double-blind, 104-week trial, which 448 patients with lupus nephritis were randomized to receive intravenous belimumab 10 mg/kg or placebo standard therapy (cyclophosphamide/azathioprine mycophenolate mofetil). Add-on was found be most effective improving primary efficacy kidney response and complete proliferative baseline urine protein/creatinine ratio under 3 g/g....
Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in phase 2 trial involving patients with lupus nephritis receiving standard therapy. In 3, randomized, controlled trial, we assigned adults biopsy-proven active 1:1 ratio to receive obinutuzumab one of two dose schedules (1000 mg on day 1 and at weeks 2, 24, 26, 52, or without week 50) placebo. All received therapy mycophenolate mofetil, along oral prednisone target 7.5...
Shared decision making in patients with glomerular disease remains challenging because outcomes important to remain largely unknown. We aimed identify and prioritize caregivers describe reasons for their choices., setting, participants, & measurementsWe purposively sampled adult from Australia, Hong Kong, the United Kingdom, States. Participants identified, discussed, ranked focus groups using nominal group technique; a relative importance score (between zero one) was calculated. Qualitative...
Background The duration of maintenance therapy after induction for lupus nephritis has not been rigorously established. A common practice is to maintain immunosuppression 1–2 years complete remission, and longer partial remission. present work addresses whether a repeat kidney biopsy might be informative in deciding who should continue or Methods large Buenos Aires nephrology unit before finalizing the decision withdraw immunosuppression. This reports on cohort 25 Hispanic patients that had...
Objective To determine whether adding obinutuzumab to standard‐of‐care lupus nephritis (LN) therapy could improve the likelihood of long‐term preservation kidney function and do so with less glucocorticoids. Methods Post hoc analyses phase II NOBILITY trial were performed. Time unfavorable outcome (a composite treatment failure, doubling serum creatinine, or death), LN flare, first 30% 40% declines in estimated glomerular filtration rate (eGFR) from baseline, chronic eGFR slope during...
Frangou, Eleni; Anders, Hans-Joachim; Bajema, Ingeborg M.; Teng, Y.K. Onno; Malvar, Ana; Rovin, Brad H.; Kronbichler, Andreas Author Information
This study investigated changes in kidney histology over time patients with lupus nephritis (LN) undergoing immunosuppressive treatment.
The kidney biopsy is used to diagnose and guide initial therapy in patients with lupus nephritis (LN). Kidney histology does not correlate well clinical measurements of injury or predict how will respond standard-of-care immunosuppression. We postulated that the gene expression profile tissue at time may differentiate who from those treatment.The 511 immune-response genes was measured biopsies 19 proliferative LN 4 normal controls. RNA extracted formalin-fixed, paraffin-embedded done flare....
The International Society of Nephrology/Renal Pathology (ISN/RPS) lupus nephritis (LN) classification is under reconsideration, given challenges with inter-rater reliability and resultant inconsistent relationship treatment response. Integration molecular classifiers into histologic evaluation can improve diagnostic precision identify therapeutic targets. This study described the between histological phenotypes clinical responses in LN. Renal compartmental mRNA abundance was measured 54...
Abstract Background Primary immunoglobulin A nephropathy (IgAN) is characterized by IgA1-dominant or codominant glomerular deposits, postulated to be galactose deficient (Gd). However, IgA deposition can also occur in nonrenal diseases such as liver cirrhosis, psoriasis and inflammatory bowel disease (‘secondary IgAN’) an incidental finding biopsies with other pathologies. glomerulonephritis resembling IgAN develop patients bacterial, mainly staphylococcal infections [staphylococcal...
O025 / #750 Topic: AS15 - Lupus Nephritis-Clinical Late-Breaking Abstract ABSTRACT CONCURRENT SESSION 04: ADVANCING LUPUS THERAPIES AND INSIGHTS 22-05-2025 1:40 PM 2:40 Background/Purpose Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is approved for B cell malignancies. In the Phase NOBILITY trial of patients with active lupus nephritis (LN; NCT02550652 ), study participants receiving obinutuzumab in addition to standard therapy were significantly more likely achieve...
PV131 / #261 Poster Topic: AS15 - Lupus Nephritis-Clinical Background/Purpose This study aims to evaluate the comparative efficacy and safety of various initial treatments for lupus nephritis through a systematic review network meta-analysis. Methods A comprehensive literature search was conducted across MEDLINE, EMBASE, Cochrane Library, LILACS from inception June 2024 in order identify randomized controlled trials (RCTs) comparing nephritis. Two reviewers independently performed data...